Future of Healthcare | Novartis

Story
May 30, 2023
The future of medicine is here
Media Release
Jun 23, 2022
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
Media Release
Jun 17, 2022
Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA
Media Release
Mar 04, 2022
Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut
Media Release
Mar 04, 2022
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire
Media Release
Mar 04, 2022
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Media Release
Mar 02, 2021
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale annuelle
Media Release
Mar 02, 2021
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Media Release
Dec 22, 2021
Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness
Media Release
Dec 02, 2021
Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms
Story
Oct 26, 2021
Demystifying the science of myelodysplastic syndromes
Media Release
Jun 23, 2021
Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts